Provided by Tiger Fintech (Singapore) Pte. Ltd.

AIM ImmunoTech

0.0949
0.0000
Volume:- -
Turnover:- -
Market Cap:6.86M
PE:-0.31
High:0.0949
Open:0.0949
Low:0.0949
Close:0.0949
Loading ...

Wellnex Life secures $9m to propel dual listing on London’s AIM market

Stockheads
·
14 Feb

Wellnex Life Secures A$9 Million for AIM Listing Pursuit

TIPRANKS
·
14 Feb

Hargreave Hale AIM VCT Announces Share Purchase and Cancellation

TIPRANKS
·
13 Feb

Tribe Technology PLC to Delist from AIM and Go Private

TIPRANKS
·
12 Feb

AIM Vaccine Submits Clinical Trial Application for mRNA Shingles Vaccine to Chinese Regulator

MT Newswires Live
·
12 Feb

AIM ImmunoTech to not proceed with offering pursuant to registration statement

TIPRANKS
·
11 Feb

AIM ImmunoTech Announces That It Will Not Proceed With an Offering Pursuant to Its Registration Statement on Form S-1 Until After It Files Its Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024

THOMSON REUTERS
·
11 Feb

Amati AIM VCT PLC Announces Share Buyback

TIPRANKS
·
11 Feb

AIM-listed companies stall on gender diversity

cityam
·
11 Feb

Argo Group to Delist from AIM Following Shareholder Approval

TIPRANKS
·
11 Feb

Gusbourne: Wine maker faces delisting from London’s AIM as shares plummet

cityam
·
10 Feb

Petra Capital Keeps Their Buy Rating on Ai-Media Technologies Limited (AIM)

TIPRANKS
·
10 Feb

AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist

TIPRANKS
·
07 Feb

AIM ImmunoTech Announces a Planned Follow-up Clinical Study Evaluating a Combination Treatment of Aim’s Ampligen® and AstraZeneca’s Flumist® to Address the Recent Avian Influenza Outbreaks

THOMSON REUTERS
·
07 Feb

Hargreave Hale AIM VCT plc: Successful AGM and Board Changes

TIPRANKS
·
07 Feb

Creightons to Switch Listing to London's AIM

Dow Jones
·
06 Feb

Creightons PLC Plans Move to AIM Market for Strategic Benefits

TIPRANKS
·
06 Feb

RA International Proposes AIM Delisting Amidst Challenging Market Conditions

TIPRANKS
·
06 Feb

Aimia Inc. (AIM) Initiated with a Buy at TD Securities

TIPRANKS
·
06 Feb

AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2

TIPRANKS
·
05 Feb